Neuphoria Therapeutics (NEUP) Payables (2020 - 2026)

Neuphoria Therapeutics (NEUP) has reported Payables for 7 consecutive years, with $627185.0 the latest figure, recorded in Q1 2026.

• On a quarterly basis, Payables fell 15.85% year-over-year to $627185.0 in Q1 2026; TTM through Mar 2026 was $627185.0, a 15.85% decrease from a year earlier, with the FY2025 full-year figure at $1.2 million, down 48.55% from the prior year.
• Payables was $627185.0 for Q1 2026 at Neuphoria Therapeutics, up from $520709.0 in the prior quarter.
• Over five years, Payables peaked at $2.3 million in Q2 2023 and troughed at $520709.0 in Q4 2025.
• A 5-year average of $1.4 million and a median of $1.3 million in 2024 frame the typical range for Payables.
• Across the five-year window, Payables surged 42.84% in 2022 and plunged 65.98% in 2025, its largest moves.
• Over 5 years, Payables stood at $2.0 million in 2022, then climbed by 17.23% to $2.3 million in 2023, then tumbled by 34.58% to $1.5 million in 2024, then sank by 65.98% to $520709.0 in 2025, then advanced by 20.45% to $627185.0 in 2026.
• The last three Payables figures came in at $627185.0 (Q1 2026), $520709.0 (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.